328 related articles for article (PubMed ID: 26372321)
1. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
Imprialos KP; Sarafidis PA; Karagiannis AI
J Hypertens; 2015 Nov; 33(11):2185-97. PubMed ID: 26372321
[TBL] [Abstract][Full Text] [Related]
2. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
4. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
5. The Beneficial Hemodynamic Actions of SGLT-2 Inhibitors beyond the Management of Hyperglycemia.
Loutradis C; Papadopoulou E; Angeloudi E; Karagiannis A; Sarafidis P
Curr Med Chem; 2020; 27(39):6682-6702. PubMed ID: 31663470
[TBL] [Abstract][Full Text] [Related]
6. Promising cardiovascular and blood pressure effects of the SGLT2 inhibitors: a new class of antidiabetic drugs.
Chrysant SG
Drugs Today (Barc); 2017 Mar; 53(3):191-202. PubMed ID: 28447076
[TBL] [Abstract][Full Text] [Related]
7. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
[TBL] [Abstract][Full Text] [Related]
9. Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
Avranas K; Imprialos K; Stavropoulos K; Lales G; Manafis A; Skalkou A; Kihm L
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):94-103. PubMed ID: 29412124
[TBL] [Abstract][Full Text] [Related]
10. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
Rajasekeran H; Cherney DZ; Lovshin JA
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
[TBL] [Abstract][Full Text] [Related]
11. Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension.
Tikkanen I; Chilton R; Johansen OE
Curr Opin Nephrol Hypertens; 2016 Mar; 25(2):81-6. PubMed ID: 26808705
[TBL] [Abstract][Full Text] [Related]
12. Recent Developments in Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors as a Valuable Tool in the Treatment of Type 2 Diabetes Mellitus.
Kumar S; Khatik GL; Mittal A
Mini Rev Med Chem; 2020; 20(3):170-182. PubMed ID: 32134370
[TBL] [Abstract][Full Text] [Related]
13. Tofogliflozin: the road goes ever on.
Pafili K; Papanas N
Expert Opin Pharmacother; 2014 Jun; 15(9):1197-201. PubMed ID: 24787286
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: A comprehensive review of clinical and preclinical studies.
Ghosh RK; Bandyopadhyay D; Hajra A; Biswas M; Gupta A
Int J Cardiol; 2016 Jun; 212():29-36. PubMed ID: 27017118
[TBL] [Abstract][Full Text] [Related]
15. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Cai X; Yang W; Gao X; Chen Y; Zhou L; Zhang S; Han X; Ji L
Obesity (Silver Spring); 2018 Jan; 26(1):70-80. PubMed ID: 29165885
[TBL] [Abstract][Full Text] [Related]
16. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus.
Jordan J; Tank J; Heusser K; Heise T; Wanner C; Heer M; Macha S; Mattheus M; Lund SS; Woerle HJ; Broedl UC
J Am Soc Hypertens; 2017 Sep; 11(9):604-612. PubMed ID: 28757109
[TBL] [Abstract][Full Text] [Related]
17. Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus.
Molugulu N; Yee LS; Ye YT; Khee TC; Nie LZ; Yee NJ; Yee TK; Liang TC; Kesharwani P
Diabetes Res Clin Pract; 2017 Oct; 132():157-168. PubMed ID: 28797524
[TBL] [Abstract][Full Text] [Related]
18. Risks Associated with SGLT2 Inhibitors: An Overview.
Singh M; Kumar A
Curr Drug Saf; 2018; 13(2):84-91. PubMed ID: 29485006
[TBL] [Abstract][Full Text] [Related]
19. The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.
Loutradis C; Papadopoulou E; Theodorakopoulou M; Karagiannis A; Sarafidis P
Future Med Chem; 2019 Jun; 11(11):1285-1303. PubMed ID: 31161798
[TBL] [Abstract][Full Text] [Related]
20. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
[Next] [New Search]